和黄医药（HCM）在夜盘交易中表现抢眼，股价大涨5.34%，引发市场关注。这一显著涨幅不仅反映了公司自身的投资吸引力，也体现了整个港股医药板块的强劲势头。
从行业角度来看，港股药品股整体呈现出持续走强的态势。多家医药公司股价出现明显上涨，其中信达生物涨幅超过9%，翰森制药和联邦制药涨幅均超过4%。和黄医药作为行业重要成员之一，显然也受益于这一积极的市场氛围。
值得注意的是，和黄医药近期持续获得南向资金青睐。数据显示，该股已连续4个交易日获得内地投资者增持。截至最新交易日收盘，港股通共持有和黄医药20552.54万股，占流通股的23.58%。这种持续的资金流入无疑为股价提供了强有力的支撑，也反映出投资者对公司未来发展前景的信心。尽管公司近期在美股市场表现略显疲软，但在港股市场的强劲表现似乎暗示了投资者对其长期价值的认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.